Biologics in Acute Burn Injury
There have been significant advances in the care of burns over the past decade. As a result of the improved survival of burn patients, attention has shifted to the optimized management of their wounds. Traditionally, autografts have been described as the gold standard treatment in cases of deep second- and third-degree burn wounds; however, they are limited especially in large surface area burns. As such, advancements have been made in the development of biologic dressings, which attempt to mimic the function of the lost epidermis and/or dermis. The ideal biologic dressing is nontoxic, lacks antigenicity, is immunologically compatible, and is sterile. Additionally, easy storage conditions, long shelf lives, and reasonable costs are key determinants of whether biologic dressings may truly be widely used in the clinical setting. Biologic dressings serve an important role as skin substitutes in the setting of acute burn injury. This review aims to summarize the multitude of available biologic dressings and their applications. Methods The PubMed and Google Scholar databases were searched for the following terms either alone or in combination: “burn injury,” “biologic membrane,” “skin substitutes,” “biosynthetic dressings,” and “acellular membrane.”
Study met both co-primary endpoints with high statistical significance, demonstrating autograft sparing and durable wound closure at three months with StrataGraft Company plans to submit Biologics License Application to the U.S. Food and Drug Administra... Regenerative Medicine Mallinckrodt, StrataGraft, regenerative tissue, burn wounds
Since the 1980s, deep and extensive skin wounds and burns are treated with autologous Split-Thickness Skin Grafts, or Cultured Epidermal Autografts (CEAs) when donor sites are limited. However, the clinical use of CEAs often remains unsatisfactory due to poor engraftment rates, altered wound healing and reduced skin functionality.In the past few decades, Mesenchymal Stromal Cells (MSCs) have raised much attention due to their anti-inflammatory, pro-trophic and pro-remodeling capacities. More specifically, gingival MSCs have been shown to possess enhanced wound healing properties compared to other tissue sources.
The objective of this study was to evaluate efficacy, safety, and duration of postoperative analgesia with liposomal bupivacaine for donor site pain in burn patients. This was an observational, case–control study including adult patients with
ConclusionsStrataGraft tissue treatment of DPT thermal burns reduced the need for autograft, resulted in wound closure and treatment-site cosmesis comparable to that of autograft, and was well tolerated.
Publication date: Available online 20 July 2019Source: BurnsAuthor(s): Sarvnaz Sepehripour, Elizabeth Chipp
There have been significant advances in the care of burns over the past decade. As a result of the improved survival of burn patients, attention has shifted to the optimized management of their wounds. Traditionally, autografts have been described as the g...
Publication date: Available online 6 June 2019Source: BurnsAuthor(s): Clifford C. Sheckter, Jeremy Goverman
Publication date: Available online 5 June 2019Source: BurnsAuthor(s): Michel H.E. Hermans
The objective of this systematic review is to compare allograft skin with other skin substitutes, which have been used in the treatment of burns.
The objective of this systematic review is to compare AS with other skin substitutes, which have been used in the treatment of burns.